Literature DB >> 33629340

Evaluation of molecular interaction, physicochemical parameters and conserved pattern of SARS-CoV-2 Spike RBD and hACE2: in silico and molecular dynamics approach.

C Chakraborty1, A R Sharma, B Mallick, M Bhattacharya, G Sharma, S-S Lee.   

Abstract

OBJECTIVE: Recent pandemic virus SARS-CoV-2 is a global warning for the healthcare system. The spike protein of virus SARS-CoV-2 is significant because of two reasons. Firstly, the spike protein of this virus binds with the human ACE2 (hACE2) receptor. Secondly, it has several antigenic regions that might be targeted for vaccine development. However, the structural analytical data for the spike protein of this virus is not available.
MATERIALS AND METHODS: Here, we performed an analysis to understand the structural two subunits of S glycoprotein (S gp) of SARS-CoV-2. Further, an analysis of secondary structure components and the tertiary structure analysis of RBD was carried out. We also performed molecular interaction analysis between S gp of this virus and hACE2 as well as between SARS-CoV S gp and hACE2 to compare the binding properties of these two viruses.
RESULTS: We noted that the molecular interaction of SARS-CoV-2 S gp and hACE2 form eleven hydrogen bonds, while the molecular interaction of SARS-CoV S gp and hACE2 receptor form seven hydrogen bonds, indicating that the molecular interaction of SARS-CoV-2 S gp and hACE2 receptor is more stable than SARS-CoV S gp and hACE2 receptor. The pairwise sequence alignment of S gp SARS-CoV and SARS-CoV-2 shows several conserved residues of these two proteins. Besides, conserved pattern analysis of SARS-CoV-2 S gp and hACE2 revealed the presence of several highly conserved regions for these two proteins. The molecular dynamics simulation shows a stable interplay between SARS-CoV-2 S gp with the hACE2 receptor.
CONCLUSIONS: The present study might help determine the SARS-CoV-2 virus entrance mechanism into the human cell. Moreover, the understanding of the conserved regions may help in the process of therapeutic development from the infection of the deadly virus.

Entities:  

Year:  2021        PMID: 33629340     DOI: 10.26355/eurrev_202102_24881

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  5 in total

Review 1.  Altered gut microbiota patterns in COVID-19: Markers for inflammation and disease severity.

Authors:  Chiranjib Chakraborty; Ashish Ranjan Sharma; Manojit Bhattacharya; Kuldeep Dhama; Sang-Soo Lee
Journal:  World J Gastroenterol       Date:  2022-07-07       Impact factor: 5.374

2.  Lichen planus drugs re-purposing as potential anti COVID-19 therapeutics through molecular docking and molecular dynamics simulation approach.

Authors:  Unnati Soni; Pratyush Singh; Om Prakash Gupta; Shalini Gupta; Saurabh Pratap Singh; Prerna Singh; Sangeeta Singh; Krishna Mishra
Journal:  J Clin Transl Res       Date:  2022-03-01

3.  Comparative genomics, evolutionary epidemiology, and RBD-hACE2 receptor binding pattern in B.1.1.7 (Alpha) and B.1.617.2 (Delta) related to their pandemic response in UK and India.

Authors:  Chiranjib Chakraborty; Ashish Ranjan Sharma; Manojit Bhattacharya; Bidyut Mallik; Shyam Sundar Nandi; Sang-Soo Lee
Journal:  Infect Genet Evol       Date:  2022-04-13       Impact factor: 4.393

4.  Omicron (B.1.1.529) - A new heavily mutated variant: Mapped location and probable properties of its mutations with an emphasis on S-glycoprotein.

Authors:  Chiranjib Chakraborty; Manojit Bhattacharya; Ashish Ranjan Sharma; Bidyut Mallik
Journal:  Int J Biol Macromol       Date:  2022-08-08       Impact factor: 8.025

5.  A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor.

Authors:  Sajjan Rajpoot; Tomokazu Ohishi; Ashutosh Kumar; Qiuwei Pan; Sreeparna Banerjee; Kam Y J Zhang; Mirza S Baig
Journal:  Drugs R D       Date:  2021-07-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.